Abilita Bio, Inc. announced that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s R&D efforts on challenging integral membrane protein targets. Financial details were not disclosed.
This exciting new collaboration aims at tackling some of the unique challenges that have limited the success of discovering and developing drugs targeting complex membrane proteins. Amgen helped define the field of biotechnology and has driven innovation through outstanding science. We look forward to working with their exceptional research teams to drive tough projects forward
said Mauro Mileni, CEO of Abilita Bio.